Cidara Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Cidara Therapeutics reports positive Phase 2b results for its lead influenza drug CD388, secures up to $339.2 million in BARDA funding, and initiates a Phase 3 trial, bolstering its financial runway despite continued net losses.
Cidara Therapeutics announced positive topline results from its Phase 2b NAVIGATE study for CD388, its influenza antiviral candidate, and reported a significantly strengthened cash position.
Cidara Therapeutics reports a net loss for Q1 2025, shifting its focus to the development of CD388 for influenza prophylaxis.
Cidara Therapeutics reacquired full rights to its influenza drug candidate CD388 and divested its commercial product Rezafungin to focus on its Cloudbreak platform.
Cidara Therapeutics reacquired global rights to CD388, its influenza drug candidate, and secured $240 million in a private placement to fund its development.
Cidara Therapeutics divested its rezafungin assets, reacquired CD388, and reported a net loss of $10.3 million for the first quarter of 2024, while shifting focus to its Cloudbreak platform.